Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented
10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MS
Additional Ocrevus real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MS
Long-term safety data and late-breaking efficacy data from Phase III trial of Enspryng (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD) will presented
South San Francisco, CA — October 1, 2023 —
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and Enspryng® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis) from October 11-13, 2023. Late-breaking data in MS includes the Phase Ib OCARINA I and Phase III OCARINA II studies, evaluating an investigational subcutaneous Ocrevus injection. In addition, the Phase II FENopta study of fenebrutinib for people living with MS, and late-breaking Enspryng data for people with NMOSD, which includes longer-term data from the Phase III SAkuraMoon study, will also be presented.
“It is gratifying to see that Ocrevus and Enspryng continue to show a favorable benefit/risk profile over many years in MS and NMOSD, and we are also pleased to share late-breaking results from our investigational MS medicine fenebrutinib and Ocrevus subcutaneous injection,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “We’ve developed these latest innovations with the goal of further improving the day-to-day lives of those living with MS.’’
See complete article here
———————————————
Stay informed with MS information, news and resources. Sign-up Here: https://bit.ly/3NkMIeR
Visit the MS Views and News articles and videos archives: https://wwwmsviewsandrelatednews.blog
Visit us on Facebook: www.facebook.com/msviewsandnews
Visit us on X (formerly Twitter): www.twitter.com/MSViewsandNews
Visit us on Instagram: www.instagram.com/msviewsandnews